HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kirn, D. H. Articles by Sugarbaker, D. J. Search for Related Content PubMed PubMed Citation Articles by Kirn, D. H. Articles by Sugarbaker, D. J.

The Journal of Thoracic and Cardiovascular Surgery, Vol 106, 696-702, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging

DH Kirn, TJ Lynch, SJ Mentzer, TH Lee, GM Strauss, AD Elias, AT Skarin and DJ Sugarbaker
Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Mass 02115.

To assess the effect of neoadjuvant platinum-based chemotherapy on resectability, stage of disease at resection, and patterns of recurrence and survival in patients with IIIA, N2 non-small-cell lung cancer, we examined the first 60 patients treated with neoadjuvant chemotherapy followed by attempted resection in our institution. Of 67 patients identified, 7 patients were ineligible because of comorbidities, 3 patients refused chemotherapy, and 1 consented but died before treatment. Fifty-six received neoadjuvant chemotherapy. Complications of chemotherapy were minor, with no deaths. Fifty-four patients had thoracotomy; 75% (n = 42) had complete resection and 25% (n = 14) had unresectable lesions. One postoperative death occurred (2%). Pathologic review of specimens and nodal groups revealed that 41% (n = 23) were downstaged, 39% (n = 22) remained stage IIIA, and 19% (n = 11) progressed. Squamous histologic type was predictive of resectability, 18 of 20 patients having resectable squamous cell tumors (p < 0.05). Actuarial survivals at 1 and 2 years were 74% and 52%, respectively. In patients with resectable tumors survivals at 1 and 2 years were 85% and 67%, respectively. For those with unresectable lesions, survivals were 43% and 14%. Relapse-free survivals at 1 and 2 years for patients with resectable lesions were 70% and 42%, respectively. Relapses were local in 25% (n = 4), at a distant site only in 50% (n = 8), combined local and distant in 25% (n = 4). Distant relapse occurred in the central nervous system only in 7 of 8 patients (88%). Complete resectability was highly predictive of improved survival (p < 0.0002). Weight loss did not affect resectability but was associated with decreased survival (p < 0.003). Neoadjuvant chemotherapy appears to improve resectability and to pathologically downstage N2 non-small-cell lung cancer from stage IIIA. Multiinstitutional randomized trials are needed to further demonstrate the efficacy of this approach.

This article has been cited by other articles:

				N. Lorent, P. De Leyn, Y. Lievens, E. Verbeken, K. Nackaerts, C. Dooms, D. Van Raemdonck, B. Anrys, J. Vansteenkiste, and The Leuven Lung Cancer Group Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience Ann. Onc., November 1, 2004; 15(11): 1645 - 1653. [Abstract] [Full Text] [PDF]

				M. K. Ferguson Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1935 - 1942. [Abstract] [Full Text] [PDF]

				J. Martin, R. J. Ginsberg, E. S. Venkatraman, M. S. Bains, R. J. Downey, R. J. Korst, M. G. Kris, and V. W. Rusch Long-Term Results of Combined-Modality Therapy in Resectable Non-Small-Cell Lung Cancer J. Clin. Oncol., April 15, 2002; 20(8): 1989 - 1995. [Abstract] [Full Text] [PDF]

				S. Margaritora, A. Cesario, D. Galetta, A. D'Andrilli, G. Macis, G. Mantini, L. Trodella, and P. Granone Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging? Eur. J. Cardiothorac. Surg., June 1, 2001; 19(6): 894 - 898. [Abstract] [Full Text] [PDF]

				S. A. Adebonojo, A. N. Bowser, D. M. Moritz, and P. C. Corcoran Impact of Revised Stage Classification of Lung Cancer on Survival: A Military Experience Chest, June 1, 1999; 115(6): 1507 - 1513. [Abstract] [Full Text] [PDF]

				H. Akamatsu, M. Terashima, T. Koike, T. Takizawa, and Y. Kurita Staging of Primary Lung Cancer by Computed Tomography-Guided Percutaneous Needle Cytology of Mediastinal Lymph Nodes Ann. Thorac. Surg., August 1, 1996; 62(2): 352 - 355. [Abstract] [Full Text]

				V. Cocquyt, W. De Neve, S. J.-P. Van Belle, N. Chanarin, N. E. Mills, C. L. Fishman, D. R. Jacobson, S.-A. McLachlan, M. Stockler, and R. Rosell Chemotherapy plus Surgery versus Surgery Alone in Non-Small-Cell Lung Cancer N. Engl. J. Med., June 16, 1994; 330(24): 1756 - 1757. [Full Text]